News

The focused update recommends an SGLT2 inhibitor (dapagliflozin or empagliflozin) in patients with HFmrEF and HFpEF to reduce the risk of heart failure hospitalization or cardiovascular death.

Amsterdam, Netherlands: The European Society of Cardiology (ESC) Guidelines on cardiomyopathies are published online today in European Heart Journal.1 This is the first international guideline document to include all cardiomyopathy...

Recommendations for patients with diabetes and existing CVD have been revised following the results of large clinical trials.

In this study, middle-aged adults with metabolic syndrome had a heart attack or stroke 2.3 years earlier than those without the collection of unhealthy traits.

FFRCT (CCTA-derived Fractional Flow Reserve) is part of a clinical pathway for evaluation and diagnosis of coronary artery disease (CAD) that provides clear insight into a patient’s condition with a patient-specific visual model of the...

NEW YORK – The Cardiovascular Research Foundation (CRF) has announced the TCT 2023 late-breaking clinical trials. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional...

The study, led by sudden cardiac arrest expert Sumeet Chugh, MD, found that 50% of individuals who experienced a sudden cardiac arrest also experienced a telling symptom 24 hours before their loss of heart function.

The OCEAN(a)-DOSE trial is a multicenter, randomized, double-blind, placebo-controlled dose-finding Phase 2 study in 281 patients with ASCVD and Lp(a) >150 nmol/L.

As a newer technique, OCT is used in only 3 percent of PCI cases, partly because of a lack of study data—something this new trial aims to change.

The results show that AI interpreted heart ultrasound images, including those taken with a handheld device, are as effective as using a typical ultrasound machine operated by an expert in measuring the pumping action of the heart.